Jadelle Contraceptive Implants up to 5 years Insertion and Removal

Similar documents
GLOBALTRAINING. IMPLANON : Reference Guide

GLOBALTRAINING. IMPLANON NXT : Reference Guide

Patient Information Publications Warren Grant Magnuson Clinical Center National Institutes of Health

Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml)

INSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF ENBREL POWDER

CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE

HOW TO USE... 5mg. Pocket Guide

Instructions for Use Enbrel (en-brel) (etanercept) for injection, for subcutaneous use Multiple-dose Vial

SELF-INJECTION GUIDE

Title: EZ-IO. Effective Date: January SOG Number: EMS Rescinds:

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

BayCuff : Self-infusion training made simple

MAKE SMART INJECTION CHOICES INJECTION PROVIDERS GUIDE FOR SAFE INJECTIONS

IMPORTANT: PLEASE READ

Instructions for Use Neulasta (nu-las-tah) (pegfilgrastim) Injection, for subcutaneous use Single-Dose Prefilled Syringe. Plunger rod Used plunger rod

Instructions for Use Enbrel (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe

Instructions for Use. Welcome!

TREMFYA (guselkumab) Information for patients

Inspection Window. Syringe Body

IMPORTANT: PLEASE READ

Acknowledgement goes to WHO for use of their hand washing technique

SCIG INFUSIONS A PRACTICAL GUIDE FOR PATIENTS

2013 MCT CPC-H Quiz #8 Chapters 13 and 14

Central venous access devices for children with lysosomal storage disorders

IV Catheter Placement

Important Safety Information for Adlyxin (lixisenatide) injection

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

INSTRUCTIONS FOR USE TYMLOS (tim lows ) (abaloparatide) injection, for subcutaneous use

Angiogram, angioplasty and stenting

PLEASE READ THESE INSTRUCTIONS BEFORE USE

Patient/Carer instructions for the administration of Subcutaneous Cytarabine

ATI Skills Modules Checklist for Central Venous Access Devices

Standard Operating Procedure for cannulation

Example CLINICAL GUIDELINES for Postpartum IUD insertion

Package leaflet: Information for the user

SHOULDER PATIENTS. Diagnostic Shoulder Arthroscopy Technique Guide

To you who will receive a T-Port PATIENT INFORMATION

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE

Instructions for Use HEMLIBRA (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use

IMPORTANT: PLEASE READ. Don t

Implanon NXT Insertion and Removal Training Course for Registered Nurses & Midwives Course Guide

This information is intended as an overview only

Imbibe Bone marrow aspiration needle. Operative technique

PLEASE READ THIS USER MANUAL BEFORE USE

Peel-Apart Percutaneous Introducer Kits for

Safe Use of Needles. Year Group: All. Document number: CSL_U02

ALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein INSTRUCTIONS FOR USE Do not Do not YOUR KIT CONTAINS:

BAYER: KOGENATE FS WITH BIOSET (Recombinant FVIII)

Cap Clip Rubber Seal Plunger Pen Body Dose Window

A patient guide to administration of subcutaneous immunoglobulin replacement therapy - using manual push technique

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11

Dynamic hip screw (sliding hip screw)

Tips for Successful Venipuncture

How to use your gonal-f pre-filled pen

How to Use ENBREL : Vial Adapter Method

PATIENT INSTRUCTIONS FOR USE SINGLE- DOSE PREFILLED SYRINGE

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

EVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3

Package leaflet: Information for the patient. Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

GUIDELINES FOR THE USE OF INVICORP INJECTION FOR MEN WITH ERECTILE DYSFUNCTION.

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

STEP-BY-STEP GUIDE TO SELF-INFUSION. Subcutaneous Administration of GAMMAGARD LIQUID

EndoRelease ENDOSCOPIC CUBITAL TUNNEL RELEASE SYSTEM

HumaPen SAVVIO INSULIN DELIVERY DEVICE INSTRUCTIONS FOR USE

I n s t r u c t i o n M a n u a l

FIRAZYR Icatibant acetate

Hip hemi-arthroplasty

CAST CARE. Helping Broken Bones Heal

MATERIAL SAFETY DATA SHEET

ZEPHYR SURGICAL IMPLANTS SÀRL

STANDARDIZED PROCEDURE REPROGRAMMING AND REFILLING INTRATHECAL BACLOFEN PUMPS and ACCESSING THE CATHETER ACCESS PORT (Adult,Peds)

Post & Pillar Biopsy Method With a vacuum assisted device

Name Partner(s) Name. Name your rat. Rat Dissection Lab

NONGYNECOLOGICAL CYTOLOGY FINE NEEDLE ASPIRATION SPECIMENS

How to Change a. Foley catheter. Patient Education Rehabilitation Nursing. Step-by-step instructions for the caregiver

Tips for Training New Customers

Stratis INSTRUCTIONS FOR USE. Needle-free Injection System. 0.5mL volume (+/-5%)

Intermittent Self-Catheterization

INFORMATION FOR THE CONSUMER

PEN USER MANUAL Byetta 5 micrograms solution for injection in pre-filled pen (exenatide)

For use only with INSTRUCTIONS FOR USE

Patient Information. Preventing and treating blood clots

MYALEPT (MAI-uh-lept) (metreleptin) for injection for subcutaneous use

A step-by-step preparation guide

ARROW EZ-IO Intraosseous Vascular Access System Procedure Template

Pfizer, BeneFIX R2 Recombinant Factor IX

CT guided lung biopsy explained

EPF Endoscopic Plantar Fasciotomy. Operative technique

Hemiarthroplasty (half hip replacement)

Instructions for Use. BASAGLAR KwikPen. insulin glargine injection (100 units/ml, 3 ml pen)

DONGBAO PEN (ELECTRONIC) INSTRUCTION MANUAL

INSTRUCTIONS FOR USE. EMGALITY TM (em-gal-it-ē) (galcanezumab-gnlm)

Education for Self Administration of Intravenous Therapy HOME IV THERAPY PICC. Portacath

Instructions for Use. HUMALOG KwikPen. insulin lispro injection (rdna origin) 100 units/ml, 3 ml pen

BLOOD COLLECTION GUIDELINES

Example Clinical Guideline for Immediate Postpartum LARC Insertion

Division 1 Introduction to Advanced Prehospital Care

Procedures/Risks:central venous catheter

Transcription:

Contraceptive Implants up to 5 years Bayer AG Global HealthCare Programs Family Planning 13342 Berlin, Germany www.bayer.com September 2017 Global HealthCare Programs Family Planning

Contraceptive Independence»» Reversible contraception long-acting: up to 5 years usage with one single administration not requiring daily, weekly, monthly or quarterly remembering or action»» Effective: as reliable as sterilization but reversible»» Convenient and discreet: Jadelle goes wherever she goes unnoticeably»» Cost-effective in long term use 1 Jadelle Contraceptive Implants up to 5 years Introduction Insertion and for doctors Removal First Implants WHO-prequalified* 2 x 75mg Implants Reference 1: Trussel J. in Hatcher H.A. Contraceptive Technology 17th Ed NY, Ardent media Inc. 1998 Global HealthCare Programs Family Planning * September 2009

Contraceptive Implants up to 5 years Introduction Introduction for doctors 4 5 On the following pages you will find the corresponding descriptions for the parts Insertion and Removal of the film. The package of Jadelle implants contains two levonorgestrel-releasing implants to be inserted subdermally into the inside of the upper arm. The basis for successful use of Jadelle implants is correct and carefully performed insertion. During insertion, special attention should be paid to the following:»» asepsis»» correct placement of the implants just beneath the skin»» careful technique to minimize tissue trauma. This will help to avoid infections and scarring of the insertion area on one hand and, on the other hand, to keep the implants from being inserted too deep in the tissue, in which case they may be displaced. If the implants are placed too deep or displaced, they will be clearly more difficult to remove than correctly placed subdermal implants. Jadelle implants provide 5 years of highly effective contraceptive protection. Since the method is intended for long-term use, it is worthwhile spending more time than usual in explaining the method to the patient and in performing the insertion.

Insertion 6 7 Insertion should preferably be performed during the first few days of menstrual bleeding, and not later than on the 7th day from the onset of menses. A gynaecological examination should be performed before the insertion of Jadelle implants as always before starting to use hormonal contraceptives. lf the patient has no contraindication to progestinonly contraception and no allergy to the antiseptic or anaesthetic to be used, the implants can be inserted according to the following procedure. Picture 2 Ask the patient to lie down on the examination table with her non-dominant arm extended on a sterile cloth on the other table, at right angles to her body. The implants will be inserted subdermally through a small 2-mm incision, in the shape of a narrow V, opening towards the armpit. 2 1 Picture 1 The following equipment is needed for the insertion: a table for the patient to lie on and another table or rest for her arm sterile surgical cloths, sterile tray for the equipment, sterile gloves (free of talc), antiseptic solution for the skin. local anaesthetic, anaesthetic needle (5-5.5 cm long) and 5 ml syringe trocar, tweezers skin closure, sterile gauze and compresses. Picture 3 Clean the patient s upper arm with an antiseptic solution, and cover the arm with either two sterile clothes or a sterile fenestrated drape. The optimal insertion area is in the medial aspect of the upper arm about 6-8 cm above the fold of the elbow. 3

8 9 4 Picture 4 Open the Jadelle pouch by pulling apart the films of the pouch and let the two implants drop on a sterile cloth. Do not touch the inside of the package or its contents with bare hands. There should be two implants. Picture 6 Jadelle is provided with a disposable trocar that is sharp enough to penetrate the skin directly. Thus the disposable trocar can be used to puncture the skin and insert the rods, without the need for an incision. 6 Note: Always use sterile gloves or forceps when handling the rods. If an implant is contaminated, e.g. falls on the floor, leave it for later disposal. Open a new package and continue with the procedure. 5 Picture 5 First determine the absence of known allergies to the anaesthetic agent or related drugs. Fill the syringe with 2-4 ml of local anaesthetic. Anaesthetize the insertion area by inserting the needle just under the skin about 5 to 5.5 cm in the directions where you are planning to introduce the trocar. Picture 7 The trocar has two marks. One mark is close to the handle and one close to the tip. When inserting Jadelle implants, the mark closest to the handle indicates, how far the trocar should be introduced under the skin before the loading of each implant. The mark closest to the tip indicates how much of the trocar should be left under the skin after the insertion of the first implant. When inserting the trocar, avoid touching the part of the trocar that will go under the skin. 7

10 11 8 Picture 8 Once the tip of the trocar is beneath the skin it should be directed along the skin horizontally by pointing slightly up-wards toward the raising the skin (tenting) to keep the implant in the subdermal plane. Throughout the insertion procedure, the trocar should be oriented with the bevel up. lt is important to keep the trocar subdermal by tenting the skin with the trocar, as failure to do so may result in deep placement of the implants causing a more difficult removal. Advance the trocar beneath the skin about 5.5 cm from the incision to the mark closest to the handle of the trocar. Do not force the trocar, and if you feel any resistance, try another direction. Picture 10 Load the first implant into the trocar either with tweezers or fingers. 10 9 Picture 9 Remove the plunger when the trocar is advanced to the correct mark. Picture 11 Push the implant gently with the plunger to the tip of the trocar until you feel resistance. Never force the plunger. 11

12 13 12 Picture 12 Hold the plunger steady and pull the trocar back along it until it touches the handle of the plunger. lt is important to keep the plunger steady and not to push the implant into the tissue. Do not completely remove the trocar until both implants have been placed. The trocar is withdrawn only to the mark closest to its tip. Picture 14 Insert the second implant next to the first one, to form a V shape. Fix the position of the first implant with the left fore-finger and advance the trocar along the side of the finger. This will ensure a suitable distance between implants. To prevent expulsions leave a distance of about 5 mm between the incision and the ends of the implants. You can check their correct position by cautious palpation of the insertion area. 14 13 Picture 13 When you can see the mark near the tip of the trocar in the incision, the implant has been released and will remain in place beneath the skin. You can check this by palpation. Picture 15 After the insertion, press the edges of the incision together and close the incision with a sterile skin closure. Suturing the incision is not necessary and may even increase scarring. 15

Removal 14 15 16 Picture 16 Cover the insertion area with a compress and wrap enough gauze around the arm to ensure haemostasis. Observe the patient at the clinic for a few minutes for signs of syncope or bleeding from the incision before she is discharged. The removal procedure described below has been used in clinical trials. Similarly to many other surgical procedures, various techniques of removal have been published. No particular removal procedure appears to have any advantage over the others. For optimal readiness, implant removal should preferably be done on certain scheduled days. The implants shall be removed very gently, and this will usually take more time than their insertion. Implants may sometimes be nicked, cut or broken during removal. If removal proves difficult, close the incision and bandage the wound, and have the patient return for another attempt. The remaining implant(s) will be easier to remove after the area is healed. A nonhormonal method of contraception shall be used until both implants have been removed. Advise the patient to keep the insertion area dry for three days and give her a copy of the Jadelle patient information leaflet in which you have noted the date of insertion. The gauze and the bandages may be removed as soon as the incision has healed usually after 3 4 days. Picture 1 The following additional equipment is needed for removal: local anaesthetic, an anaesthetic needle and a syringe a scalpel two different types of forceps (Mosquito and Crile) a skin closure, gauze and compresses. 1

16 17 2 Picture 2 Locate the implants by palpation, possibly marking their position with a marker pen. If they cannot be palpated, they may be located by ultrasound or soft tissue X-ray. lnject a small amount of local anaesthetic under the ends of the implants that are closer to each other. Anaesthetic injected over the implants may obscure their position and make removal more difficult. If necessary, more anaesthetic can be given in small amounts at a time. Picture 4 Push each implant with your fingers gently towards the incision. When the tip is visible in the incision, grasp it with the Mosquito forceps. Use a scalpel to very gently open the tissue capsule around the implant. 4 3 Picture 3 Make a 4-mm incision with the scalpel close to the ends of the implants. Keep the incision small. Picture 5 Grasp the end of the implant with the second forceps (Crile). 5

6 Picture 6 Remove the implant gently. Repeat the procedure for the second implant. Measure the length of the removed implants to make sure the patient had two Jadelle implants and not other contraceptive implants. The length should be 43 mm. After the procedure is completed, close the incision and bandage it as after insertion. The arm should be kept dry for a few days. lf the patient wishes to continue using the method, a new set of Jadelle implants can be inserted through the same incision, in the same or the opposite direction. Following removal pregnancy may occur at any time. Abbreviated Prescribing Information: This section is intended as general reference source on Jadelle for the international reader. For detailed information, please refer to the prescribing Information of your national regulatory authority. Jadelle 2x75mg implants Composition: The product consists of two implants to be inserted subdermally. Each implant contains 75 mg levonorgestrel. The release rate of levonorgestrel is about 100 microgram/day at one month after insertion, declining to about 40 microgram/day within one year, to about 30 microgram/day within 3 years, and to about 25 microgram/ day within five years. Indication: Contraception. Method of administration: For subcutaneous use for long-term (up to five years) contraception. The user must be informed that Jadelle can be removed at her request at any time. Training is required for the insertion and removal procedures, which should be done by a health care professional and the insertion instructions must be closely followed. Jadelle should be inserted within 7 days from the onset of menstrual bleeding. If the implants are inserted at any other time, pregnancy must be reliably excluded before insertion and an additional non-hormonal contraceptive method used for at least 7 days after the insertion. Contraindications: Hypersensitivity to levonorgestrel or any other component of Jadelle, Undiagnosed abnormal vaginal bleeding, Diagnosed or suspected sex hormone dependent neoplasia, Acute liver disease, Benign or malignant liver tumor, Thromboembolic disease. Special precautions: See full prescribing information. Most common undesirable effects: Headache, nervousness, dizziness, nausea, changed menstrual bleeding (frequent, irregular or prolonged menstrual bleeding, spotting amenorrhea), cervicitis, vaginal discharge, genital pruritus, pelvic pain, breast pain, weight gain. For further details see the full prescribing information. Marketing authorization holder: Bayer AG (local subsidiary). Global HealthCare Programs Family Planning